iGMDRD464


Canonical SMILES: CN1C2=C(C=C(C=C2)OC3=CC(=NC=C3)C4=NC=C(N4)C(F)(F)F)N=C1NC5=CC=C(C=C5)C(F)(F)F

InChI: InChI=1S/C24H16F6N6O/c1-36-19-7-6-15(10-17(19)34-22(36)33-14-4-2-13(3-5-14)23(25,26)27)37-16-8-9-31-18(11-16)21-32-12-20(35-21)24(28,29)30/h2-12H,1H3,(H,32,35)(H,33,34)

InChI Key: YABJJWZLRMPFSI-UHFFFAOYSA-N

Loading, please wait...
Standard Name
Pubchem CID
Drug Status
Drug Type
Standard NameRAF265
Pubchem CID11656500
Drug StatusAlone
Drug TypeSmall Molecule

Drug Class:

Kinase inhibitor

Drug Targets:

BRAFKDR

Drug-model tissue-cancer distribution: Bubble Plot

BREAStissue: BREAS cancer: BREAST model num: 0BREASTtissue: BREAST cancer: undefined model num: 1undefinetissue: undefine cancer: undefined model num: 0undefinedtissue: undefined cancer: PANCAN model num: 4BOWEtissue: BOWE cancer: BOWEL model num: 0BOWELtissue: BOWEL cancer: Colorectal Cancer model num: 1LUNtissue: LUN cancer: LUNG model num: 0LUNGtissue: LUNG cancer: Non-Small Cell Lung Cancer (NSCLC) model num: 1

Drug-gene pathway enrichments

5reactome: Signal Transduction3reactome: Signaling by NTRKs3reactome: Signaling by Receptor Tyrosine Kinases3kegg: HTLV-I infection - Homo sapiens (human)2kegg: Gastric cancer - Homo sapiens (human)2kegg: Longevity regulating pathway - Homo sapiens (human)2reactome: Generic Transcription Pathway2kegg: Hepatocellular carcinoma - Homo sapiens (human)2reactome: MAPK family signaling cascades2kegg: Chronic myeloid leukemia - Homo sapiens (human)

Drug-gene GO enrichments

5CC: cytosol4CC: cytoplasm4CC: nucleus3CC: membrane3BP: positive regulation of apoptotic process3MF: protein binding3BP: apoptotic process3MF: protein homodimerization activity3BP: protein export from nucleus2BP: mitochondrial fusion

Drug-Gene: Aster Plot


Loading, please wait...
Gene ID
Gene Name
Model Num.
7514 XPO1 1
3845 KRAS 2
581 BAX 1
Showing 1 to 3 of 3 rows

Gene in drug-gene network: Network Plot

tipifarnib-P2tipifarnib-P2BI-2536BI-2536GW-843682XGW-843682XAZD-1775AZD-1775PaclitaxelPaclitaxelGSK-461364GSK-461364XL-880XL-880PF 184PF 184XPO1XPO1selumetinib in BRAF mutant tumorsselumetinib in BRAF mutant tumorskinetin ribosidekinetin ribosideBMS-536924BMS-536924serdemetanserdemetanPRIMA-1PRIMA-1CIL56CIL56SepantroniumSepantroniumNPC26NPC26tamatinibtamatinibNVP-AUY922NVP-AUY922Nsc 632839Nsc 632839PRIMA-1METPRIMA-1METnutlin 3nutlin 3BAXBAXPP-30PP-30MEK inhibitorsMEK inhibitorsGefitnibGefitnibCHEMBL399379CHEMBL399379cetuximabcetuximabErlotinibErlotinibPanitumumabPanitumumabPD0325901PD0325901NSC141540NSC141540PI3K pathway inhibitorsPI3K pathway inhibitorsSarcolysinSarcolysinRefametinibRefametinibRegorafenibRegorafenibTrametinibTrametinibKRASKRASRAF265RAF265

Models in RAF265

Model
Level
Reference ID
Tissue
Cancer
Drug
Clinical Response
Source
EXP(JAGGED1) protein MCLP BREAST undefined RAF265 resistance in vitro
EXP(BAX) protein MCLP undefined PANCAN RAF265 resistance in vitro
EXP(EGFR_pY1173) protein MCLP undefined PANCAN RAF265 resistance in vitro
EXP(HSP27_pS82) protein MCLP undefined PANCAN RAF265 sensitivity in vitro
EXP(CRM1) protein MCLP undefined PANCAN RAF265 resistance in vitro
MUT(KRAS) gene 25199829 BOWEL Colorectal Cancer RAF265 sensitivity in vivo
MUT(KRAS) gene 25199829 LUNG Non-Small Cell Lung Cancer (NSCLC) RAF265 sensitivity in vivo
Showing 1 to 7 of 7 rows

​​​​